Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

Aim: To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer perspective. Methods: The frequencies of grade ≥3 hematologic AEs that occurred in >1% of patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin
Format: Article
Language:English
Published: Becaris Publishing Limited 2024-12-01
Series:Journal of Comparative Effectiveness Research
Subjects:
cost management
maintenance therapy
niraparib
ovarian cancer
parp inhibitor
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items